Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 8/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409011 | 0.92 | MAPK13 (0.53) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL5403354 | 0.91 | ALDH1A1 (0.50) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL5409022 | 0.91 | MAPK13 (0.52) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL5401470 | 0.89 | MAPK13 (0.56) | MAPK13MAPK12MAPK11MAPK14RAB9A | |
| SCHEMBL5554647 | 0.87 | MAPK13 (0.42) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL5403248 | 0.87 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL5407137 | 0.86 | MAPK13 (0.55) | MAPK13MAPK12MAPK11MAPK14RAB9A | |
| SCHEMBL5393306 | 0.86 | MAPK13 (0.61) | MAPK13MAPK12MAPK11MAPK14RAB9A | |
| SCHEMBL5400048 | 0.86 | MAPK14 (0.64) | MAPK13MAPK12MAPK11MAPK14RAB9A | |
| SCHEMBL5392778 | 0.86 | MEN1 (0.53) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658288-B1 | 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-12-05 | — | — | EP | claimed |
| US-7250431-B2 | neuropeptide Y(NPY) receptor antagonists; useful in the treatment of obesity; such as 4-methoxy-N-{4-[5-(2-methyl-benzoyl)-thiazol-2-ylamino]-phenyl}-benzenesulfonamide | HOFFMANN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | claimed |
| JP-2007501823-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1658288-A1 | 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-24 | — | — | EP | claimed |
| WO-2005014592-A1 | 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | claimed |
| US-20050038089-A1 | neuropeptide Y(NPY) receptor antagonists; useful in the treatment of obesity; such as 4-methoxy-N-{4-[5-(2-methyl-benzoyl)-thiazol-2-ylamino]-phenyl}-benzenesulfonamide | HOFFMAN-LA ROCHE INC. | 2005-02-17 | — | — | US | claimed |
| EP-1658288-B1 | 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-12-05 | — | — | EP | disclosed |
| US-7250431-B2 | neuropeptide Y(NPY) receptor antagonists; useful in the treatment of obesity; such as 4-methoxy-N-{4-[5-(2-methyl-benzoyl)-thiazol-2-ylamino]-phenyl}-benzenesulfonamide | HOFFMANN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1658288-A1 | 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005014592-A1 | 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20050038089-A1 | neuropeptide Y(NPY) receptor antagonists; useful in the treatment of obesity; such as 4-methoxy-N-{4-[5-(2-methyl-benzoyl)-thiazol-2-ylamino]-phenyl}-benzenesulfonamide | HOFFMAN-LA ROCHE INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038089-A1 | neuropeptide Y(NPY) receptor antagonists; useful in the treatment of obesity; such as 4-methoxy-N-{4-[5-(2-methyl-benzoyl)-thiazol-2-ylamino]-phenyl}-benzenesulfonamide | NPY5R, NPY1R, NPY4R | MAPK13 1352/4885MAPK12 1899/4885MAPK11 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.